Pregled bibliografske jedinice broj: 496838
EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS ON ERYTHROPOIESIS AND KIDNEY FUNCTION IN RENAL TRANSPLANT PATIENTS
EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS ON ERYTHROPOIESIS AND KIDNEY FUNCTION IN RENAL TRANSPLANT PATIENTS // Kidney Blood Pressure Research
Zagreb, Hrvatska, 2009. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 496838 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
EFFECT OF ANGIOTENSIN RECEPTOR BLOCKERS ON ERYTHROPOIESIS AND KIDNEY FUNCTION IN RENAL TRANSPLANT PATIENTS
Autori
Orlić, Lidija ; Sladoje-Martinović, Branka
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Kidney Blood Pressure Research
/ - , 2009
Skup
5th Central European Meeting on Hypertension
Mjesto i datum
Zagreb, Hrvatska, 22.10.2009. - 25.10.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
renal transplant patients; angiotensin receptor blockers; erythropoesis
Sažetak
Hypertension is present in about 60-80% of renal transplant patients (RTx). Angiotensin I receptor blockers (ARBs) are often given to those patients. It was reported that an intact renin-angiotensin system (RAS) may be an important factor of erythropoiesis. It is also known that ARBs may deteriorate kidney function.. The goal of this work was to examine influence of ARBs on erythropoiesis and kidney function in RTx. In this study, we analysed 47 RTx (19 men and 28 women, mean age 47, 1±9, 6 years) with stable transplant function. The time elapsed from transplantation to the introduction of ARBs was minimum 6 months (average 3, 7±2, 5 years). Excluding criteria were: serum creatinin value >140 µmol/L, taking ACE inhibitors and gastrointestinal bleeding. All patients received the triple immunosuppressive therapy (corticosteroid, mycophenolate mofetil, calcineurin inhibitor). Red blood cells count (RBCC), serum hemoglobin, hematocrit and serum creatinine values were measured before ARBs and 6 and 12 months after introducing therapy. At the end of follow up, there were no significant differences in RBCC, serum hemoglobin (p=0.08) and serum creatinine value (p=0.59). There were significant differences in hematocrit (p=0.03), after 6 and 12 months. In 14 patients whose hemoglobin values at the beginning were above 150 g/Lat baseline, a significant decrease was seen during follow up (p=0.003). We can conclude that there are no changes in serum creatinine values, i.e. kidney function in RTx treated with ARBs. There was no effect on RRCC and hemoglobin values. However, significant differences in RBCC and hemoglobin values were observed on
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Lidija Orlić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE